J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector. The FDA granted approval to AstraZeneca AZN a ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.